25-Oct-2018 - CureVac AG

CureVac enters clinical phase with mRNA vaccine

First data expected on intramuscular application of the newly developed vaccine

CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced the initiation of its Phase I dose-escalation clinical trial with the novel mRNA-based rabies vaccine, CV7202. This is the first-in-human clinical trial of CureVac’s naturally optimized mRNA technology delivered using a lipid nanoparticle (LNP), tailored to provide the vaccine with a strong, safe and persistent immune response. The study will assess the safety, reactogenicity, and the potential protective immune response of the vaccine. 

CV7202 is a prophylactic mRNA-based vaccine encoding the rabies virus glycoprotein, RABV-G, formulated with next generation LNP. CureVac’s platform of mRNA-based therapeutics optimizes the properties of mRNA, including stability and immunogenicity, using enhanced sequences of naturally occurring building blocks. CureVac’s technology stimulates the immune system to mount a response against an antigen of choice, potentially providing potent prophylactic vaccines for the prevention of infectious diseases, such as rabies, as well as immunotherapies for the treatment of cancer. 

“The first study participant enrolled in this rabies clinical trial is a significant milestone for CureVac, and allows the company to demonstrate its ability to trigger an immune response in vaccine naïve populations, which is different from vaccines just boosting an already existing immune response such as a flu vaccination,” said Dan Menichella, Chief Executive Officer of CureVac. “Our goal is to significantly improve today’s commercial three-to-five shot regimen rabies vaccines with a one or two shot solution that has a markedly longer duration. With this trial, we are taking an important step toward further validating the potential of our mRNA-based vaccine platform and therapeutic pipeline that will soon include additional oncology and rare diseases candidates.”

Facts, background information, dossiers
  • therapeutics
  • mRNA vaccines
  • vaccination
More about CureVac